| Secondary |
| Drug Use For Unknown Indication |
37.7% |
| Product Used For Unknown Indication |
28.7% |
| Atrial Fibrillation |
10.7% |
| Pulmonary Embolism |
4.1% |
| Neuralgia |
2.5% |
| Cardiac Failure |
1.6% |
| Osteoporosis |
1.6% |
| Pain |
1.6% |
| Pyrexia |
1.6% |
| Thrombosis |
1.6% |
| Amyotrophic Lateral Sclerosis |
0.8% |
| Cardiac Disorder |
0.8% |
| Cerebral Thrombosis |
0.8% |
| Colitis Ulcerative |
0.8% |
| Depression |
0.8% |
| Embolism |
0.8% |
| Hyperaesthesia |
0.8% |
| Hyperlipidaemia |
0.8% |
| Hypertriglyceridaemia |
0.8% |
| Infection |
0.8% |
|
| Prothrombin Level Decreased |
23.1% |
| International Normalised Ratio Increased |
15.4% |
| Gastrointestinal Haemorrhage |
10.3% |
| Pyrexia |
5.1% |
| Subdural Haemorrhage |
5.1% |
| Tricuspid Valve Incompetence |
5.1% |
| Cerebral Haemorrhage |
2.6% |
| Drug Interaction |
2.6% |
| Haematoma |
2.6% |
| Haemoglobin Decreased |
2.6% |
| Haemorrhage |
2.6% |
| Hallucination |
2.6% |
| International Normalised Ratio Fluctuation |
2.6% |
| Intra-abdominal Haemorrhage |
2.6% |
| Occult Blood Positive |
2.6% |
| Prothrombin Level |
2.6% |
| Prothrombin Level Increased |
2.6% |
| Prothrombin Time Shortened |
2.6% |
| Respiratory Depression |
2.6% |
| Septic Embolus |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.3% |
| Atrial Fibrillation |
13.6% |
| Drug Use For Unknown Indication |
7.8% |
| Cardiac Failure |
7.2% |
| Diabetes Mellitus |
4.7% |
| Multiple Myeloma |
4.4% |
| Essential Hypertension |
4.2% |
| Hypertension |
3.4% |
| Osteoporosis |
3.2% |
| Renal Failure Chronic |
3.0% |
| Rheumatoid Arthritis |
2.8% |
| Hyperlipidaemia |
2.1% |
| Epilepsy |
1.9% |
| Neuralgia |
1.5% |
| Local Anaesthesia |
1.3% |
| Primary Hypothyroidism |
1.3% |
| Pulmonary Hypertension |
1.3% |
| Blood Follicle Stimulating Hormone Decreased |
1.1% |
| Blood Luteinising Hormone Decreased |
1.1% |
| Diuretic Therapy |
1.1% |
|
| Aplasia Pure Red Cell |
11.6% |
| Syncope |
11.6% |
| Hypotension |
8.1% |
| Renal Failure |
7.0% |
| Hypoglycaemia |
4.7% |
| Osteonecrosis |
4.7% |
| Tachycardia |
4.7% |
| Tooth Disorder |
4.7% |
| Tremor |
4.7% |
| Atrial Fibrillation |
3.5% |
| Duodenal Ulcer Haemorrhage |
3.5% |
| Fatigue |
3.5% |
| International Normalised Ratio Increased |
3.5% |
| Muscle Twitching |
3.5% |
| Orthostatic Hypotension |
3.5% |
| Pyrexia |
3.5% |
| Renal Failure Acute |
3.5% |
| Ventricular Tachycardia |
3.5% |
| Vomiting |
3.5% |
| Vulvovaginal Dryness |
3.5% |
|
| Interacting |
| Atrial Fibrillation |
28.6% |
| Product Used For Unknown Indication |
14.3% |
| Cardiac Failure |
7.1% |
| Chronic Obstructive Pulmonary Disease |
7.1% |
| Ill-defined Disorder |
4.8% |
| Infection |
4.8% |
| Pneumonia |
4.8% |
| Skin Candida |
4.8% |
| Tinea Infection |
4.8% |
| Tinea Versicolour |
4.8% |
| Cardiovascular Disorder |
2.4% |
| Depressed Mood |
2.4% |
| Epilepsy |
2.4% |
| Pulmonary Embolism |
2.4% |
| Skin Infection |
2.4% |
| Urinary Tract Infection |
2.4% |
|
| International Normalised Ratio Increased |
25.0% |
| Prothrombin Level Decreased |
18.8% |
| Haemorrhage |
12.5% |
| Drug Interaction |
6.3% |
| Gastrointestinal Haemorrhage |
6.3% |
| Haematoma |
6.3% |
| International Normalised Ratio Decreased |
6.3% |
| Melaena |
6.3% |
| Rash |
6.3% |
| Syncope |
6.3% |
|
